Newly approved additives will be used to made surgically implanted devices safer, more successful

September 19, 2012 by Jennifer Lanthier
Professor Paul Santerre is chief scientific officer for Interface Biologics. Credit: John Guatto

What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.

Through its licensing partner, AngioDynamics, IBI has just cleared a major regulatory hurdle that will allow a medical device using its polymer-based additives to be used in the United States.

"This is a transformative event for Interface Biologics and signals the beginning of what we hope will be a very successful commercialization effort," said Thomas Reeves, president and of IBI.

IBI's additives are used to improve devices such as ports or catheters which are implanted in the body. These , marketed under the name Endexo, have now been cleared by the U.S. (FDA) for use in AngioDynamics' BioFlo PICC – a peripherally inserted central catheter - in the United States.

The body's own defense systems are primed to attack anything foreign – including devices that could help save a patient's life. The result: blood and tissue build up in or around the device, clogging blood vessels and causing worsening side effects or symptoms for patients and even requiring doctors to remove or replace the devices.

Endexo aims to change that.

Added to the device during the , Endexo alters the surface of the device, making it harder for blood or tissue to build up and clog the device. And, unlike coatings that are sometimes applied to to reduce , Endexo does not break down quickly or alter the physical properties of the device.

AngioDynamics had already received regulatory clearance to sell its BioFlo PICC  with the Endexo technology in Canada. Both clinical results and sales have been impressive, said Reeves. A recent study at a Vancouver hospital reported dramatic clinical differences between the company's PICCs and those of a competitor.

"The BioFlo PICC had a 48% reduction in occlusions – the inability to infuse or aspirate – and a 38% reduction in the need to use t-PA, which is a drug used to break up blood clots," Reeves said. "It also showed a 37% reduction in deep vein thrombosis, a very serious and life-threatening complication.

"This 'real world' data is the key behind driving commercialization of this new product so we hope to see further studies published on the clinical benefits of the BioFlo PICC with Endexo technology in the near future."

Joseph DeVivo, president and CEO of AngioDynamics, called Bioflo with Endexo technology "a truly disruptive technology" because it reduces thrombus without the use of blood-thinning drugs such as heparin, antibiotics, or antimicrobials generally associated with coatings.

Clearing this latest regulatory hurdle opens up a much larger market for the product. AngioDynamics holds an estimated 15% of the $375 million U.S. PICC market. Analysts expect the company to apply for FDA approval for additional products using the IBI technology such as BioFlo ports and BioFlo dialysis .

"This technology, which started in Professor Santerre's lab at the U of T, and was spun out as a separate company in 2001, has been funded by Canadian venture capitalists (current investors are BDC, Covington,  and the MaRS Investment Accelerator Fund), and has been resident at MaRS since the facility's inception," Reeves said. "By clearing this latest regulatory hurdle, IBI is on its way to being one of the great successes in the life sciences 'ecosystem' that we are all trying to engender.

"We're proud of the Canadian success story that IBI has become."

Explore further: FDA should invest in developing a new medical device clearance process

Related Stories

Commercializing medical device innovation

July 16, 2012

(Medical Xpress) -- New medical devices take a long time to reach the market – and many never make it. Jon Johnson, a researcher at Cambridge’s Institute for Manufacturing, is looking at ways of making the process ...

Recommended for you

3-D bioprinted human cartilage cells can be implanted

March 23, 2017

Swedish researchers at Sahlgrenska Academy and Chalmers University of Technology have successfully induced human cartilage cells to live and grow in an animal model, using 3-D bioprinting. The results will move development ...

MRI-powered mini-robots could offer targeted treatment

March 7, 2017

Invasive surgical techniques - cutting through the breastbone for open heart surgery or making a large incision to inspect an abdominal tumor - allow physicians to effectively treat disease but can lead to sometimes serious ...

New method rescues donor organs to save lives

March 6, 2017

A multidisciplinary team led by Gordana Vunjak-Novakovic, Mikati Foundation Professor of Biomedical Engineering and Medical Sciences at Columbia Engineering, and Matt Bacchetta, associate professor of surgery at Columbia ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.